Login to Your Account

Financings Roundup

Wednesday, February 6, 2013
Kineta Inc., of Seattle, and RLB Holdings formed a partnership to develop Kineta's drug candidates ShK-186 and rOAS. ShK-186 is in development or autoimmune disease, and rOAS is a candidate for viral illnesses.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription